文献速递儿科与产科急症

静脉瑞芬太尼患者自控镇痛与肌注哌替啶用于分娩镇痛的比较(RESPITE):一项开放标签、多中心、随机对照试验

Intravenous remifentanil patient-controlled analgesia versus intramuscular pethidine for pain relief in labour (RESPITE): an open-label, multicentre, randomised controlled trial.
PubMed 文献 · Lancet · 2018-08-13
一句话结论与肌注哌替啶相比,静脉瑞芬太尼PCA使分娩镇痛中转为硬膜外镇痛的比例减半(19% vs 41%,RR 0.48)。

RESPITE研究为14个英国产科单位开展的开放标签、多中心、随机对照试验,纳入≥37周、单胎头位、要求阿片类镇痛的分娩产妇,1:1随机接受静脉瑞芬太尼PCA(40 μg 按需 bolus,锁定时间2 min)或肌注哌替啶(100 mg 每4 h,24 h内最多400 mg)。主要终点为入组后因分娩镇痛接受硬膜外镇痛的比例,瑞芬太尼PCA组19%(39/201)vs 哌替啶组41%(81/199),RR 0.48(95%CI 0.34-0.66),p<0.0001。研究期间两组均未发生直接归因于镇痛药的严重不良事件或药物反应。作者认为该结果挑战了肌注哌替啶作为分娩镇痛常规标准治疗的地位。

要点

  • 分娩镇痛中,静脉瑞芬太尼PCA(40 μg 按需 bolus,锁定2 min)较肌注哌替啶(100 mg 每4 h,24 h内最多400 mg)使硬膜外转换比例从41%降至19%(RR 0.48,95%CI 0.34-0.66,p<0.0001)。
  • 适用人群为≥16岁、>37周妊娠、单胎头位、分娩中要求阿片类镇痛的产妇,来自14个英国产科单位。
  • 研究期间未发生直接归因于瑞芬太尼PCA或哌替啶的严重不良事件或药物反应。
  • 作者认为该结果挑战了肌注哌替啶作为分娩镇痛常规标准治疗的地位。
  • 试验为开放标签设计,受试者和医护人员未对分组设盲。

适用人群与场景

  • 年龄≥16岁、妊娠>37周、分娩中、单胎头位、要求阿片类镇痛的产妇,来自14个英国产科单位。

处置流程与药物剂量

  • 静脉瑞芬太尼PCA组:40 μg 按需 bolus,锁定时间2 min,静脉给药。
  • 肌注哌替啶组:100 mg 每4 h,24 h内最多400 mg,肌内注射。

研究设计与关键结果

  • 开放标签、多中心、随机对照试验,14个英国产科单位,201例随机至瑞芬太尼PCA组、200例至哌替啶组(哌替啶组1例撤回知情同意,199例纳入分析)。
  • 主要终点硬膜外转换比例:瑞芬太尼PCA组19%(39/201)vs 哌替啶组41%(81/199),RR 0.48(95%CI 0.34-0.66),p<0.0001。
  • 研究期间无直接归因于两种镇痛药的严重不良事件或药物反应。

证据类型、等级与局限

  • 证据类型:开放标签、多中心、随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,静脉瑞芬太尼PCA较肌注哌替啶使分娩镇痛中硬膜外转换比例减半,该结果挑战了肌注哌替啶作为分娩镇痛常规标准治疗的地位。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: About a third of women receiving pethidine for labour pain subsequently require an epidural, which provides effective pain relief but increases the risk of instrumental vaginal delivery. Remifentanil patient-controlled analgesia (PCA) in labour is an alternative to pethidine, but is not widely used. We aimed to evaluate epidural analgesia progression among women using remifentanil PCA compared with pethidine.

METHODS: We did an open-label, multicentre, randomised controlled trial in 14 UK maternity units. We included women aged 16 years or older, beyond 37 weeks' gestation, in labour with a singleton cephalic presentation, and who requested opioid pain relief. We randomly assigned eligible participants (1:1) to either the intravenous remifentanil PCA group (40 μg bolus on demand with a 2 min lockout) or the intramuscular pethidine group (100 mg every 4 h, up to 400 mg in 24 h), using a web-based or telephone randomisation service with a minimisation algorithm for parity, maternal age, ethnicity, and mode of labour onset. Because of the differences in routes of drug administration, study participants and health-care providers were not masked to the group allocation. The primary outcome was the proportion of women who received epidural analgesia after enrolment for pain relief in labour. Primary analyses were unadjusted and analysed by the intention-to-treat principle. This study is registered with the ISRCTN registry, number ISRCTN29654603.

FINDINGS: Between May 13, 2014, and Sept 2, 2016, 201 women were randomly assigned to the remifentanil PCA group and 200 to the pethidine group. One participant in the pethidine group withdrew consent, leaving 199 for analyses. The proportions of epidural conversion were 19% (39 of 201) in the remifentanil PCA group and 41% (81 of 199) in the pethidine group (risk ratio 0·48, 95% CI 0·34-0·66; p<0·0001). There were no serious adverse events or drug reactions directly attributable to either analgesic during the study.

INTERPRETATION: Intravenous remifentanil PCA halved the proportion of epidural conversions compared with intramuscular pethidine. This finding challenges routine pethidine use as standard of care in labour.

FUNDING: National Institute for Health Research Clinician Scientist Award.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Wilson MJA, MacArthur C, Hewitt CA, et al. Intravenous remifentanil patient-controlled analgesia versus intramuscular pethidine for pain relief in labour (RESPITE): an open-label, multicentre, randomised controlled trial. Lancet. 2018. PMID: 30115484. doi:10.1016/S0140-6736(18)31613-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。